NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to share several updates.
多倫多和以色列海法,2024年1月17日(GLOBE NEWSWIRE)——爲脊髓外傷患者開發生物引導外泌體療法的生物製藥公司NurexOne Biologic Inc.(多倫多證券交易所股票代碼:NRX)(FSE:J90)(“公司” 或 “NurexOne”)很高興分享幾項最新消息。
The collaborative agreement between NurExone and Inteligex Inc. ("Inteligex"), announced in October 2023, to expand the Company's portfolio, is now officially underway. This collaboration, aimed at combining Inteligex's more than twenty years of experience in cell-based therapies and NurExone's innovative exosome platform to develop therapies for patients with chronic spinal cord injuries, was approved for grant funding, to be disbursed over the course of the next two years, by the Israel-Canada bilateral Eureka program.
NurexOne與Inteligex Inc.(“Inteligex”)於2023年10月宣佈的擴大公司投資組合的合作協議現已正式生效。這項合作旨在將Inteligex在細胞療法領域二十多年的經驗與NurexOne爲慢性脊髓損傷患者開發療法的創新外泌體平台相結合,已獲得以色列-加拿大雙邊尤里卡計劃批准的撥款,將在未來兩年內發放。
Dr. Lior Shaltiel, CEO of NurExone, expressed his excitement about the kick-off of this project stating, "This collaboration reiterates the importance and utility of the ExoTherapy platform in developing drug delivery systems of the future. As part of this collaboration, we will use our platform to produce and load exosomes from Inteligex's cell line to deliver combination regenerative therapy for Spinal Cord Injury (SCI) patients. This win-win collaboration will expand our potential markets and is in line with our belief of patient, first."
NurexOne首席執行官Lior Shaltiel博士對該項目的啓動表示興奮,他說:“這次合作重申了Exotherapy平台在開發未來藥物遞送系統中的重要性和實用性。作爲此次合作的一部分,我們將使用我們的平台從Inteligex的細胞系中生產和加載外泌體,爲脊髓損傷(SCI)患者提供聯合再生療法。這種雙贏合作將擴大我們的潛在市場,也符合我們以患者爲先的信念。”
Dr. Paul Bradshaw, CEO of Inteligex, stated that "Spinal cord injury is the single most expensive healthcare condition in the world. I believe that a combinatorial multi-faceted approach to treatment of chronic SCI like the one in this project can both make a difference in patient's lives and save the healthcare system billions of dollars. Moreover, if the therapy has an easy delivery method, we can expand to countries where there is a massive barrier to any therapy or treatment and do a bit of good for humanity."
Inteligex首席執行官保羅·布拉德肖博士表示:“脊髓損傷是世界上最昂貴的醫療保健疾病。我相信,像這個項目那樣採用多方面的組合方法來治療慢性脊髓損傷,既可以改變患者的生活,又可以爲醫療系統節省數十億美元。此外,如果該療法具有易於實施的方法,我們可以擴展到任何療法或治療都存在巨大障礙的國家,併爲人類帶來一點好處。”
NurExone Announces Engagement Agreement with bullVestor
NurexOne 宣佈與 BullveStor 簽訂訂合作協議
The Company has entered into an agreement (the "Agreement") with bullVestor Medien GmbH ("BullVestor") to assist with and enhance awareness of the Company's products and services using advertising and communications, some of which may constitute investor relations activities pursuant to the policies of the TSX Venture Exchange. The advertising and communications will occur in German-speaking countries (Germany, Austria and Switzerland).
公司已與BullveStor Medien GmbH(“BullveStor”)簽訂協議(“協議”),以利用廣告和傳播來協助和提高人們對公司產品和服務的認識,根據多倫多證券交易所風險交易所的政策,其中一些可能構成投資者關係活動。廣告和傳播將在德語國家(德國、奧地利和瑞士)進行。
The Agreement is effective for four months from the effective date and the total consideration payable to BullVestor is CAD$300,000 on the effective date. The consideration does not include any securities of the Company. BullVestor does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest. Aside from this engagement, the Company does not have any relationship with BullVestor.
該協議自生效之日起四個月內生效,自生效之日起,應付給BullveStor的總對價爲300,000加元。該對價不包括本公司的任何證券。BullveStor在公司或其證券中沒有任何直接或間接的權益,也沒有任何收購此類權益的權利或意圖。除此次合作外,該公司與BullveStor沒有任何關係。
BullVestor is located in Austria.
BullVestor 位於奧地利。
About NurExone Biologic Inc.
關於 Nurexone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
NurexOne Biologic Inc. 是一家在多倫多證券交易所上市的製藥公司,該公司正在開發一個平台,以非侵入性方式向遭受創傷性脊髓損傷的患者提供生物引導的exOtherapy。exOtherapy在以色列理工學院的動物研究中得到了概念性的證實。NurexOne正在將這種治療方法轉化爲人類,該公司擁有理工學院和特拉維夫大學頒發的全球獨家許可,用於該技術的開發和商業化。
For additional information, please visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
欲了解更多信息,請訪問 或者關注 NurexOne 領英, 推特, Facebook,或 YouT。
欲了解更多信息,請聯繫:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Lior Shaltiel 博士
首席執行官兼董事
電話:+972-52-4803034
電子郵件:info@nurexone.com
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
論文資本公司
投資關係-加拿大
電話:+1 905-347-5569
電子郵件:IR@nurexone.com
Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
伊娃·路透博士
投資關係-德國
電話:+49-69-1532-5857
電子郵件:e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
前瞻性陳述
This press release contains certain "forward-looking statements", that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the collaboration project with Inteligex and the grant funding pursuant thereto; the Agreement, the term of the Agreement and the fees payable thereunder. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
本新聞稿包含某些 “前瞻性陳述”,反映了公司當前對其未來業績的預期和預測。儘可能使用諸如 “可能”、“將”、“應該”、“可以”、“期望”、“計劃”、“打算”、“預測”、“相信”、“估計” 或 “潛在” 等詞語或這些詞語的負面或其他變體,或類似的詞語或短語來識別這些前瞻性陳述。本新聞稿中的前瞻性陳述包括但不限於與Inteligex合作項目及根據該項目提供的補助金相關的陳述;協議、協議條款以及根據協議應付的費用。這些陳述反映了管理層當前的信念,並基於截至本文發佈之日管理層目前獲得的信息。
In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate, the general market conditions, the ability to secure additional funding for the collaboration with Inteligex and our ability to work collaboratively with Inteligex.
在撰寫本新聞稿中的前瞻性陳述時,我們運用了多個重要假設,包括我們經營的行業和國家的總體商業和經濟狀況、總體市場狀況、爲與Inteligex合作獲得額外資金的能力以及我們與Inteligex合作的能力。
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property, dependence on the Company's strategic partners and the risks discussed under the heading "Risk Factors" on pages 29 to 36 of the Company's Annual Information Form dated March 30, 2023, a copy of which is available under the Company's SEDAR+ profile at . These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
前瞻性陳述涉及重大風險、不確定性和假設。許多因素可能導致實際業績、業績或成就與前瞻性陳述中討論或暗示的結果存在重大差異。這些風險和不確定性包括但不限於與公司早期發展階段、迄今爲止收入不足、政府監管、其產品的市場接受度、快速的技術變革、對關鍵人員的依賴、對公司知識產權的保護、對公司戰略合作伙伴的依賴以及公司2023年3月30日年度信息表第29至36頁在 “風險因素” 標題下討論的風險相關的風險,該表的副本可在公司的SEDAR+個人資料下找到,網址爲。應仔細考慮這些因素,讀者不應過分依賴前瞻性陳述。儘管本新聞稿中包含的前瞻性陳述基於管理層認爲合理的假設,但公司無法向讀者保證實際業績將與這些前瞻性陳述一致。這些前瞻性陳述自本新聞稿發佈之日起作出,除非法律要求,否則公司沒有義務對其進行更新或修改以反映新的事件或情況。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。